Cascadian Therapeutics
Cascadian Therapeutics, Inc. (Form: 3, Received: 03/20/2017 20:36:38)
FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Walker Luke Nathaniel

2. Date of Event Requiring Statement (MM/DD/YYYY)
3/9/2017 

3. Issuer Name and Ticker or Trading Symbol

Cascadian Therapeutics, Inc. [CASC]

(Last)        (First)        (Middle)

C/O CASCADIAN THERAPEUTICS, INC., 2601 4TH AVE., SUITE 500

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                            _____ 10% Owner
___ X ___ Officer (give title below)          _____ Other (specify below)
SVP, Clinical Development /

(Street)

SEATTLE, WA 98121       

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed (MM/DD/YYYY)

 

6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person


Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock   3990   D    

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy)     (1) 9/30/2019   Common Stock   2500   $35.88   D    
Stock Option (right to buy)     (2) 12/1/2019   Common Stock   334   $41.52   D    
Stock Option (right to buy)     (3) 12/12/2020   Common Stock   1250   $28.44   D    
Stock Option (right to buy)     (4) 12/12/2021   Common Stock   2500   $10.44   D    
Stock Option (right to buy)     (5) 12/16/2022   Common Stock   1250   $10.56   D    
Stock Option (right to buy)     (6) 9/24/2023   Common Stock   5834   $21.06   D    
Stock Option (right to buy)     (7) 5/17/2024   Common Stock   8334   $6.90   D    
Stock Option (right to buy)     (8) 5/17/2024   Common Stock   20834   $6.90   D    
Stock Option (right to buy)     (9) 1/11/2027   Common Stock   35100   $4.64   D    
Restricted Share Unit (RSU)     (10) 1/11/2021   Common Stock   7800     (11) D    

Explanation of Responses:
( 1)  The option was 100% vested on September 16, 2015.
( 2)  The option was 100% vested on December 1, 2015.
( 3)  The option was 100% vested on December 12, 2016.
( 4)  The option vests and is exercisable at the rate of 1/4th of the total shares on December 12, 2014 and then 1/48th of the total shares vest and are exercisable monthly thereafter, with 100% vested and exercisable on December 12, 2017, subject to the holder's continued employment with the issuer on each vesting date.
( 5)  The option vests and is exercisable at the rate of 1/4th of the total shares on December 16, 2015 and then 1/48th of the total shares vest and are exercisable monthly thereafter, with 100% vested and exercisable on December 16, 2018, subject to the holder's continued employment with the issuer on each vesting date.
( 6)  The option vests and is exercisable at the rate of 1/4th of the total shares on September 24, 2016 and then 1/48th of the total shares vest and are exercisable monthly thereafter, with 100% vested and exercisable on September 24, 2019, subject to the holder's continued employment with the issuer on each vesting date.
( 7)  The option vests and is exercisable at the rate of 1/4th of the total shares on May 17, 2017 and then 1/48th of the total shares vest and are exercisable monthly thereafter, with 100% vested and exercisable on May 17, 2020, subject to the holder's continued employment with the issuer on each vesting date.
( 8)  The option vests and is exercisable at the rate of 1/4th of the total shares on April 1, 2017 and then 1/48th of the total shares vest and are exercisable monthly thereafter, with 100% vested and exercisable on April 1, 2020, subject to the holder's continued employment with the issuer on each vesting date.
( 9)  The option vests and is exercisable at the rate of 1/4th of the total shares on January 11, 2018 and then 1/48th of the total shares vest and are exercisable monthly thereafter, with 100% vested and exercisable on January 11, 2021, subject to the holder's continued employment with the issuer on each vesting date.
( 10)  Twenty-five percent of the shares underlying the RSU vest on each of January 11, 2018, January 11, 2019, January 11, 2020 and January 11, 2021, subject to the holder's continued employment with the issuer on each vesting date.
( 11)  Approximately 67% of each RSU represents a contingent right to receive approximately 0.67 share of the issuer's Common Stock upon vesting and approximately 33% represents a contingent right to receive cash upon vesting, which cash will be used to facilitate the holder's satisfaction of U.S. federal tax obligations in connection with the vesting of the RSUs.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Walker Luke Nathaniel
C/O CASCADIAN THERAPEUTICS, INC.
2601 4TH AVE., SUITE 500
SEATTLE, WA 98121


SVP, Clinical Development

Signatures
/s/ Julia M. Eastland as attorney-in-fact for Luke N. Walker 3/20/2017
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

LIMITED POWER OF ATTORNEY

The undersigned hereby constitutes and appoints Julia M. Eastland, as long as she is providing services to Cascadian Therapeutics, Inc. (the "Company"), the undersigned's true and lawful attorney-in-fact to:
(1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of the Company, Forms 3, 4s and 5s in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder;
(2) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute any such Forms 3, 4s and 5s and timely file such forms with the Securities and Exchange Commission and any stock exchange or similar authority; and
(3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to such attorney-in-fact full power and authority to do and perform each and every act and thing whatsoever requisite, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution and revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that such attorney-in-fact, in serving in such capacity at the request of the undersigned, is not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with
Section 16 of the Exchange Act.

The undersigned agrees that such attorney-in-fact may rely entirely on information furnished orally or in writing by the undersigned to such attorney-in-fact. The undersigned also agrees to indemnify and hold harmless the Company and such attorney-in-fact against any losses, claims, damages or liabilities (or actions in these respects) that arise out of or are based on any untrue statement or omission of necessary facts in the information provided by the undersigned to such attorney-in-fact for purposes of executing, acknowledging, delivering and filing Forms 3, 4s or 5s (including amendments thereto) and agrees to reimburse the Company and such attorney-in-fact for any legal or other expenses reasonably incurred in connection with investigating or defending against any such loss, claim, damage, liability or action.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4s and 5s with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorney-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of March 17, 2017.

/s/ LUKE N. WALKER
Luke Nathaniel Walker, M.D.